About 40 million people suffer from lactose intolerance in America. If Ritter Pharmaceuticals Inc. (RTTR) has any say, that number will soon be zero.

CEO Andrew Ritter told TheStreet at the LD Micro conference in Los Angeles that his company is getting closer to developing a treatment for lactose intolerance. If successful, it could serve as a one-time treatment that will end the symptoms for the millions who are forced to avoid dairy or face dire consequences. 

For more from the LD Micro Conference in La:

TheStreet at LD Micro: What CEO Dave Callaway Sees in Small Caps This Year

STK Owner The ONE Group Is Carving Its Own Unique Space in the Dining Experience

SRAX Chief Weighs in as Company Readies for Cryptocurrency Dividend

Snap Interactive's New Blockchain App Could Flip Video Chat on Its Head

Micro Caps Take the Spotlight at LD Micro Conference - Here's What to Expect

Lexaria Biosciences Is Ready for the Legal Cannabis Boom

Here's How Small Cap Scissor Company Acme United Is Benefitting From Amazon

Here's How Cloud Computing Firm Fusion Is Using M&A to Get Ahead

Biotech Innovator Oncolix Utilizing Novel Treatment to End Women's Cancers

Amazing Energy Isn't Afraid to Take on Big Oil

More from Video

Tilray CEO: Surging Cannabis Industry Is a Threat to Food and Drug Players

Tilray CEO: Surging Cannabis Industry Is a Threat to Food and Drug Players

How This Former VC Player Became CEO of $2 Billion Cannabis Company Tilray

How This Former VC Player Became CEO of $2 Billion Cannabis Company Tilray

Lee Munson: Not Peak FANG Yet

Lee Munson: Not Peak FANG Yet

Even Standing Desk Company Varidesk Is Watching How the Trump Tariffs Play Out

Even Standing Desk Company Varidesk Is Watching How the Trump Tariffs Play Out

Jim Cramer on Bank of America, Tariffs and the Goldman Sachs CEO Change

Jim Cramer on Bank of America, Tariffs and the Goldman Sachs CEO Change